How is a plexiform neurofibroma diagnosed?

How to Diagnose Plexiform Neurofibroma

Plexiform neurofibroma is diagnosed through an integrated approach combining clinical assessment, advanced imaging (MRI with specific sequences), image-guided core needle biopsy with histologic evaluation, and molecular testing to distinguish it from more aggressive entities and guide management. 1

Clinical Assessment

Look for these specific features:

• Association with NF1: While plexiform neurofibromas occur almost exclusively in NF1 patients, isolated cases without NF1 are extremely rare 2, 3
• Physical findings: Large, lobulated masses involving subcutaneous and cutaneous tissues with infiltrative invasion of deeper structures 4
• Timing: Usually diagnosed during childhood, presenting as bulging, deforming masses that can involve multiple nerve branches 5, 6
• Symptoms: Pain, functional impairment, cosmetic deformity 7

Imaging Protocol

Pre-biopsy Imaging Strategy

Use MRI as the primary modality with these specific sequences:

• Target radiologically concerning areas showing increased FDG-PET avidity or decreased apparent diffusion coefficient (ADC) on diffusion-weighted imaging 1
• Characteristic imaging features include:
  • "Target sign" appearance on ultrasound, CT, and MRI 4
  • Fat and fluid contents within the mass 4
  • Simultaneous involvement of multiple tissue planes 4

Purpose of Imaging

• Confirm diagnosis
• Delineate involved structures
• Identify multiple concerning regions for targeted biopsy 1
• Monitor for malignant transformation 4

Biopsy Technique (Critical for Accurate Diagnosis)

Use image-guided percutaneous core biopsy with 14-18 gauge needles, obtaining at least 6 core biopsies from multiple radiologically concerning areas. 1

Specific Biopsy Requirements:

• Target multiple regions: Sample different areas showing concerning features on imaging (FDG-PET avid regions, areas with decreased ADC) 1
• Label each site clearly: Use separate containers marked by biopsy location (e.g., "region #1, FDG-PET avid region") 1
• Tissue processing: Place no more than 2 cores per formalin-fixed, paraffin-embedded block to minimize tissue depletion 1

Common Pitfall to Avoid:

Do not rely on single-site sampling—these tumors are highly heterogeneous, and inadequate sampling may miss areas of malignant transformation or atypical features 1.

Histologic Evaluation

Evaluation must be performed by a subspecialized pathologist and include assessment of these standardized features: 1

Diagnostic Criteria for Plexiform Neurofibroma:

• Retained neurofibroma architecture without cytologic atypia or hypercellularity 1
• Inconspicuous mitotic figures 1
• Absence of necrosis 1

Mandatory Histologic Features to Report:

1. Cytologic atypia (present or absent)
2. Loss of neurofibromatous architecture (present or absent)
3. Hypercellularity (present or absent)
4. Mitotic count per 10 high-power fields
5. Necrosis (present or absent) 1

Molecular Testing (Essential for Integrated Diagnosis)

For clinically or radiologically worrisome noncutaneous lesions, molecular profiling is recommended to identify features that would reclassify the tumor. 1

When to Perform Molecular Testing:

• Any worrisome clinical or radiological features
• Noncutaneous lesions in NF1 patients
• Cases with concerning histologic features on initial evaluation 1

Key Molecular Features to Assess:

CDKN2A/B status:

• Homozygous deletion/inactivation → reclassifies as ANNUBP even with neurofibroma histology 1
• Heterozygous inactivation + ≥1 atypical histologic feature → ANNUBP 1

Markers of malignant transformation:

• SUZ12, EED, or TP53 inactivating mutations → reclassifies as MPNST 1
• Significant aneuploidy (segmental gain/loss of ≥8 chromosome arms) → reclassifies as MPNST 1

Recommended Testing Approach:

Use comprehensive next-generation sequencing panel with copy number and zygosity assessment 1. Alternative: targeted panel for SUZ12, EED, TP53 mutations plus array comparative genomic hybridization for copy number analysis 1.

Critical Point:

Molecular features supersede morphologic features in the 2025 integrated classification—a lesion with neurofibroma histology but CDKN2A/B homozygous deletion is reclassified as ANNUBP; one with SUZ12/EED/TP53 mutations or significant aneuploidy is reclassified as MPNST, regardless of histology 1.

Immunohistochemistry

While not definitive, these markers guide further molecular workup:

• Reduced H3K27me3 staining suggests PRC2 complex inactivation (SUZ12/EED mutations) 1
• p16 loss suggests CDKN2A/B inactivation 1
• Abnormal p53 expression warrants molecular assessment 1

Important caveat: Immunohistochemistry alone has false positives and false negatives—always confirm with molecular sequencing 1.

Diagnostic Algorithm Summary

1. Clinical suspicion → NF1 patient with concerning mass
2. MRI with DWI and/or FDG-PET → identify concerning regions
3. Image-guided core biopsy → minimum 6 cores from multiple sites (14-18G needles)
4. Histologic evaluation → assess all 5 standardized features
5. Molecular testing (if worrisome features) → NGS panel with copy number analysis
6. Integrated diagnosis → combine histology + molecular features per 2025 classification 1

This integrated approach is essential because approximately 10% of plexiform neurofibromas may harbor molecular features indicating higher risk, fundamentally changing management even when histology appears benign 1.